Introduction：Basic information about Enfortumab Vedotin CAS 1346452-25-2, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Enfortumab Vedotin Basic information
| Product Name: | Enfortumab Vedotin |
| Synonyms: | Enfortumab Vedotin;Research Grade Enfortumab(DHJ41001);Enfortumab;Research Grade Enfortumab;Enfortumab vedotin-ejfv (anti-Nectin-4) |
| CAS: | 1346452-25-2 |
| MF: | |
| MW: | 0 |
| EINECS: | |
| Product Categories: | |
| Mol File: | Mol File |
|
Enfortumab Vedotin Chemical Properties
| form | Liquid |
| color | Colorless to light yellow |
Safety Information
Enfortumab Vedotin Usage And Synthesis
| Uses | Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable maleimidocaproylvaline-citrulline linker (SGD-1006). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma[1][2]. |
| Synthesis | Synthesis of enfortumab vedotin
|
| References | [1] Halford Z, et al. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma. Ann Pharmacother. 2021 Jun;55(6):772-782. DOI:10.1177/1060028020960402
[2] Chang E, et al. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2021 Feb 15;27(4):922-927. DOI:10.1158/1078-0432.CCR-20-2275 |
Enfortumab Vedotin Preparation Products And Raw materials
